Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | LPAR1 | Q92633 | 7/20 | 0.50 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.50 |
| ▸ | LPAR2 | Q9HBW0 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.45 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.44 |
| ▸ | PRKCG | P05129 | 1/20 | 0.44 |
| ▸ | PRKCB | P05771 | 1/20 | 0.44 |
| ▸ | PRKCA | P17252 | 1/20 | 0.44 |
| ▸ | PRKCH | P24723 | 1/20 | 0.44 |
| ▸ | PRKCI | P41743 | 1/20 | 0.44 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.44 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.44 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.44 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.44 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1932689 | 1.00 | USP2 (0.52) | USP2LPAR1LPAR3LPAR2HTT | |
| SCHEMBL13966877 | 1.00 | USP2 (0.52) | USP2LPAR1LPAR3LPAR2HTT | |
| SCHEMBL10133136 | 1.00 | USP2 (0.52) | USP2LPAR1LPAR3LPAR2HTT | |
| SCHEMBL8641219 | 1.00 | USP2 (0.52) | USP2LPAR1LPAR3LPAR2HTT | |
| SCHEMBL16338301 | 1.00 | USP2 (0.52) | USP2LPAR1LPAR3LPAR2HTT | |
| SCHEMBL8644294 | 1.00 | USP2 (0.52) | USP2LPAR1LPAR3LPAR2HTT | |
| SCHEMBL8646854 | 1.00 | USP2 (0.52) | USP2LPAR1LPAR3LPAR2HTT | |
| SCHEMBL2979667 | 1.00 | USP2 (0.52) | USP2LPAR1LPAR3LPAR2HTT | |
| SCHEMBL13966880 | 1.00 | USP2 (0.52) | USP2LPAR1LPAR3LPAR2HTT | |
| Ammonia Solution, Strong SCHEMBL16798365 | 0.98 | USP2 (0.50) | USP2LPAR1LPAR3LPAR2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9814777-B2 | Targeting lipids | ARBUTUS BIOPHARMA CORPORATION (CA) | 2017-11-14 | — | — | US | disclosed |
| US-9814777-B2 | Targeting lipids | ARBUTUS BIOPHARMA CORPORATION (CA) | 2017-11-14 | — | — | US | disclosed |
| US-20160375137-A9 | TARGETING LIPIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2016-12-29 | — | — | US | disclosed |
| US-20140179761-A1 | TARGETING LIPIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2014-06-26 | — | — | US | disclosed |
| US-20140179761-A1 | TARGETING LIPIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2014-06-26 | — | — | US | disclosed |
| US-20120183602-A1 | LIPID FORMULATION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120183602-A1 | LIPID FORMULATION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-8158601-B2 | Lipid formulation | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158601-B2 | Lipid formulation | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20100324120-A1 | LIPID FORMULATION | BANK OF AMERICA, N.A. | 2010-12-23 | — | — | US | disclosed |
| US-20100324120-A1 | LIPID FORMULATION | BANK OF AMERICA, N.A. | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120183602-A1 | LIPID FORMULATION | CETP, LIPA, SGMS1 | USP2 3816/4885LPAR1 91/4885LPAR3 107/4885 |
| US-20100324120-A1 | LIPID FORMULATION | CETP, LIPA, SGMS1 | USP2 3816/4885LPAR1 91/4885LPAR3 107/4885 |
| US-20140179761-A1 | TARGETING LIPIDS | LY96, ABHD10, APOB | USP2 1457/4885LPAR1 4/4885LPAR3 16/4885 |
| US-20160375137-A9 | TARGETING LIPIDS | LY96, ABHD10, APOB | USP2 1457/4885LPAR1 4/4885LPAR3 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.